Augmedix, Inc. (NASDAQ:AUGX) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Matt Chesler - Investor Relations Manny Krakaris - Chief Executive Officer Paul Ginocchio - Chief Financial Officer Conference Call Participants Jared Hasson - William Blair Neil Chatterji - B. Riley Securities Allen Klee - Maxim Group Operator Greetings, welcome to Augmedix Incorporated 2022 Fourth Quarter Earnings Conference Call. At this time, all participants will be in listen-only mode. A questi ...

Company Overview - Augmedix offers real-time and asynchronous virtual medical documentation for clinicians, connecting them with the Notebuilder Platform through mobile devices and proprietary software[9] - The company serves over 20 health systems[9] - Augmedix's solutions can save clinicians up to 3 hours per day, boost productivity by as much as 20%, and improve work-life satisfaction by 40%[8] - Augmedix has a large addressable market, with approximately 295,000 clinicians in the U S [14] Financial Performance - Augmedix achieved $8 8 million in Q4 2022 revenue, representing a 126% year-over-year net revenue retention[9] - The company's revenue for 2022 was $30 9 million, compared to $22 2 million in 2021, indicating a 40% year-over-year growth[9] Market Opportunity and Strategy - Augmedix estimates a $6 billion U S market opportunity[14] - The company sees a $1B+ expansion opportunity within existing customers[14] - The company's strategy involves moving from point solution sales to portfolio sales, with a focus on EHR integration to enable hyper-scaling[17] Technology and Solutions - Augmedix uses a building block approach that combines automated speech recognition, natural language processing, large language models, and clinical datasets[22] - The company's Notebuilder Platform uses Natural Language Processing (NLP) and Large Language Models (LLMs) to enhance documentation[12]

Augmedix, Inc. (NASDAQ:AUGX) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ji-Yon Yi - Gilmartin Group LLC Manny Krakaris - Chief Executive Officer Paul Ginocchio - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Marc Wiesenberger - B. Riley Securities Charlie Montang - Lake Street Capital Markets, LLC Allen Klee - Maxim Group Operator Greetings and welcome to Augmedix, Inc. Third Quarter 2022 Earnings Call. At this time, all participant ...

Financial Data and Key Metrics Changes - Revenue for Q2 2022 was $7.3 million, representing a 42% year-over-year growth from $5.2 million in Q2 2021 [9][16] - Dollar-based net revenue retention for Q2 2022 was 131%, up from 113% in Q2 2021 [16] - Adjusted gross margin for Q2 2022 was 44%, slightly down from 45% in the same period last year [17] - Total operating expenses for Q2 2022 were $9.3 million, with non-GAAP operating expenses growing 33% year-over-year [17] - Adjusted EBITDA loss for Q2 2022 was $5.3 million, compared to a loss of $4 million in Q2 2021 [18] Business Line Data and Key Metrics Changes - The average number of clinicians in service rose 49% year-over-year in Q2 2022, building on a 53% growth in Q1 2022 [16] - The company added several enterprise customers in Q2 2022, indicating successful conversion of its pipeline [9] Market Data and Key Metrics Changes - The company reported a significant increase in bookings in June 2022, marking the best month ever for bookings [9][28] - The total addressable market (TAM) is estimated at $6 billion, with over 57,000 physicians representing a TAM of over $1 billion [25][26] Company Strategy and Development Direction - The company is focused on expanding enterprise customer relationships and enhancing its AI-driven core platform [8] - A partnership with Adventist Health aims to automate medical documentation across multiple specialties [10] - The company is developing new products, including a pre-charting solution and a self-serve product, to address administrative workflow challenges [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth opportunities and the ability to reduce cash burn as gross profit outpaces operating expenses [19][21] - The company expects revenue growth in Q3 2022 to be in the range of 37% to 39% year-over-year, with revenue guidance of approximately $7.7 million to $7.8 million [20] Other Important Information - The company has over two years of operating runway and options to extend that runway without issuing additional equity [19] - The partnership with Google has been deepened to include a systematic go-to-market collaboration [11] Q&A Session Summary Question: Can you provide more detail on the Adventist relationship? - The company identifies ideal candidates for its services based on work relative value units (wRVU) and time spent in EHR per visit, leading to significant penetration growth at Adventist [24] Question: Can you provide insights on June bookings? - June was the best month for bookings, with a shortening of the sales cycle noted [28] Question: What is the proportion of new clinicians using live versus notes? - The percentage of revenue from notes is expanding, though it is not yet the majority [32] Question: Is there potential to expand services to nurses and support staff? - The company has recently deployed solutions addressing nurses' needs, indicating a significant market opportunity [36] Question: Can you discuss the potential of the Trio partnership? - The partnership with Trio Health has potential for additional revenue, particularly through the CIIC membership [40] Question: How do currency fluctuations affect the business? - The strengthening of the US dollar has provided more buying power in operations based in India and Bangladesh [56] Question: What is the outlook for cash flow breakeven? - The company has over two years of operating runway, with expectations for revenue growth to outpace operating expenses [59]

Augmedix, Inc. (NASDAQ:AUGX) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Caroline Paul - Investor Relations Manny Krakaris - Chief Executive Officer and Board Member Paul Ginocchio - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Marc Wiesenberger - B Riley FBR Brooks O’Neil - Lake Street Capital Markets Allen Klee - Maxim Group Operator Hello and welcome to the Augmedix, Inc. 2022 First Quarter Earnings Conference Call. All participants wi ...